Acorda Therapeutics, Inc. reaffirmed earnings guidance for the year 2023. For the full year 2023, the company continues to target INBRIJA U.S. net revenue to be $38 million - $42 million and AMPYRA net revenue to be $65 million - $70 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.879 USD | +9.88% | -2.33% | -94.17% |
15/04 | Acorda Therapeutics Delisted from Nasdaq, Now Trading on OTC Pink Market | MT |
2023 | Transcript : Acorda Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023 |
1st Jan change | Capi. | |
---|---|---|
-94.17% | 529K | |
+10.44% | 107B | |
+0.82% | 106B | |
+6.72% | 23.47B | |
-13.89% | 21.9B | |
-6.64% | 18.77B | |
-37.26% | 17.85B | |
-10.98% | 16.78B | |
+8.67% | 14.41B | |
+41.08% | 12.86B |
- Stock Market
- Equities
- ACOR.Q Stock
- ACOR Stock
- News Acorda Therapeutics, Inc.
- Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023